Business Context and Reporting Period
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics (XmAb) for cancer and autoimmune diseases. This Form 10-K covers the fiscal year ended December 31, 2025. The company operates as a single segment and relies on licensing and collaboration agreements for revenue, as it has no commercial product sales of its own.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $125.6 million | $110.5 million |
| Net Loss (Attributable to Xencor) | $(91.9) million | $(232.6) million |
| Operating Loss | $(177.5) million | $(178.4) million |
| Research & Development Expenses | $239.4 million | $227.7 million |
| Cash, Cash Equivalents, and Marketable Securities | $610.8 million | $706.7 million |
| Accumulated Deficit | $(796.0) million | $(704.0) million |
Revenue Composition (2025): Royalties ($80.3 million), Milestones ($45.3 million). No license revenue was recognized in 2025.
Liquidity: The company reported a net increase in cash of $13.1 million for the year, driven by investing activities (sales of marketable securities) and financing activities, offset by operating cash outflows of $135.1 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $15.1 million (13.7%) compared to 2024. This was primarily driven by higher royalty revenue from Alexion (Ultomiris) and Incyte (Monjuvi), and milestone payments from Incyte and Amgen.
- Net Loss Improvement: The net loss attributable to Xencor decreased significantly from $232.6 million in 2024 to $91.9 million in 2025. This improvement was largely due to a $101.5 million gain on marketable equity securities (primarily Zenas BioPharma) and higher interest income, partially offset by operating expenses.
- Operating Expenses: R&D expenses increased by $11.7 million, driven by higher external and internal costs for key programs (XmAb819, XmAb657, XmAb942). General and administrative expenses remained relatively flat.
- Portfolio Adjustments: The company paused development of vudalimab and decided not to initiate expansion cohorts for XmAb808 in combination with pembrolizumab, resulting in wind-down costs of $17.2 million.
Guidance, Outlook, and Risks
Outlook and Guidance: Management believes existing cash, cash equivalents, marketable securities, and expected milestone/royalty payments will fund operations through 2028. No specific financial guidance for 2026 was provided in the text.
Key Developments:
- XmAb819: Presented initial Phase 1 data in renal cell carcinoma showing a 70% disease control rate.
- XmAb942: Initiated a global Phase 2b study (XENITH-UC) for ulcerative colitis.
- Plamotamab: Initiated a Phase 1b proof-of-concept study for rheumatoid arthritis.
- XmAb657: Initiated a Phase 1 study for idiopathic inflammatory myopathies.
Risks and Contingencies:
- Internal Controls: The company previously identified material weaknesses in internal controls (related to non-routine transactions and tax legislation) which led to restatements of 2023 and 2024 financials. Management states these were remediated during 2025, and controls were deemed effective as of December 31, 2025.
- Intellectual Property Litigation: Merus N.V. filed a patent infringement lawsuit in August 2024. While the court granted a motion to dismiss the initial complaint in September 2025, Merus filed an amended complaint in November 2025. The company is also pursuing inter partes review of Merus patents.
- Capital Requirements: As a clinical-stage company, Xencor expects to continue incurring significant losses and will require additional financing to complete clinical development.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $610.8 million cash balance to fund operations through 2028, considering the high burn rate of clinical trials.
- Revenue Concentration: Assess reliance on royalty revenue from Ultomiris (Alexion) and Monjuvi (Incyte), which comprised the majority of 2025 revenue.
- Investment Gains: Note that the significant reduction in net loss was driven by a $101.5 million unrealized gain on marketable equity securities (Zenas), which is non-operating and volatile.
- Legal Exposure: Monitor the status of the Merus patent litigation and the outcome of the inter partes review proceedings.
- Internal Control Remediation: Confirm the sustained effectiveness of the remediated internal controls over financial reporting in future filings.